Additional Relevant Details Currently, the GMI-1271 drug being developed by GlycoMimetics is in the Phase 1/2 trial.  The Company expects the data from the trial to be released in Q2 of 2016.  The drug is to be used in combination with chemotherapy for the treatment of acute myeloid leukemia (AML).  The Company also announced that when "used in combination with G-CSF (filgrastim) to mobilize and enrich progenitor T cells known as T memory stem (Tscm) and T central memory (Tcm) cells, which provide improved reconstitution and persistence".